A型激酶锚定蛋白的结构和生物学功能

cAMP依赖性蛋白激酶A(PKA)通过A型激酶锚定蛋白(Akinaseanchorproteins,AKAPs)靶向亚细胞位点,PKA识别它的底物或效应蛋白,从而引导并放大cAMP信号的生物学效应。AKAPs是功能上相关的调节蛋白家族,具有结合PKA的保守区和引导AKAPPKA复合体到亚细胞位点的靶向区。AKAPs不仅与PKA相互作用,也与其它信号分子作用,主要是磷酸酶和激酶。AKAPPKA复合体可汇集和整合来自各种通路的信号,该复合体不仅可局部增强cAMP和其它信号,通过降低PKA的基础活性,还可发挥远程效应。     

蛋白激酶A锚定蛋白95的生物学功能

蛋白激酶A锚定蛋白95(AKAP95),具有在细胞核内锚定蛋白激酶A(PAK)的作用.最近的研究结果发现AKAP95参与细胞内许多重要的生命过程,如参与细胞分裂染色体集缩的建立和集缩状态的保持,参与基因表达调控、DNA复制以及维持mRNA的稳定,参与胚胎发育,参与细胞凋亡以及参与细胞周期调控等.简要介绍了PKA和蛋白激酶A锚定蛋白(AKAPs),并综述了AKAP95的结构、细胞周期分布以及新近发现的AKAP95的重要生物学功能.     

AKAP9及其与疾病关系的研究进展

A型激酶锚定蛋白9(A-kinase anchoring protein9,AKAP9)是A型激酶锚定蛋白家族(AKAPs)中的重要成员。A型激酶锚定蛋白(AKAPs)广泛存在于多种细胞,在底物附近募集不同的信号传导酶,从而将上游激活子和下游作用因子有效的组装在一个大分子信号传导复合物中,整合了共同调节细胞底物的磷酸化的各种信号分子,从而保证了信号传导的特异性和准确性。研究发现,AKAP9可通过和蛋白激酶A(protein kinase A,PKA)直接相连,调控PKA对N-甲基-D-天冬氨酸受体(N-methyl-D-aspartic acid receptor,NMDA)受体的磷酸化,进而参与神经系统功能活动。在心血管系统,AKAP9还可通过与PKA,蛋白磷酸酶1(protein phosphatase 1,PP1)相互作用,调节钾通道的离子流,影响复极化进程,与长QT综合征密切相关。并且对不同病人的基因组大数据筛选发现,AKAP9基因突变存在于多种疾病中,说明AKAP9不仅在正常的生物体中发挥重要作用,而且其异常与多种疾病发生密切相关。因此,本文将着重从AKAP9生理功能及其与疾病之间关系这两方面作一综述。     

心脏A激酶锚定蛋白AKAP概述

A激酶锚定蛋白是一组结构各异但功能相关的蛋白质.因其具有与PKA结合的特性而得名.目前研究发现AKAP除了作为A激酶锚定分子外,还是会聚和传播高度有序的细胞信号的一个平台,是细胞生命活动的重要调控者.AKAP在心肌细胞的收缩、能量代谢、离子通道的启闭、基因表达等方面均扮演重要角色.     

蛋白激酶A对小鼠受精卵早期发育过程中M期促进因子活性的影响

为研究小鼠体内 1 细胞期受精卵M期蛋白激酶A(PKA)对M期促进因子 (MPF)活性的影响 ,应用PKA激动剂cAMP及热稳定性抑制剂PKI显微注射入 1 细胞期受精卵内 ,观察MPF及PKA活性变化 .未经注射的对照组MPF活性在分裂期增高 ,分裂间期下降 ;而PKA活性在进入分裂期下降 ,分裂间期升高 .cAMP组PKA活性维持高峰值 ,直至注射HCG后 2 8h ,MPF活性高峰延迟 30min出现 ;PKI显微注射组PKA活性低 ,而MPF活性在注射HCG后 2 7 5h即达高峰 ,且维持高峰时间达1 5h .结果表明 ,PKA活性在细胞周期中也呈波动性 ,间期活性高 ,分裂期活性低 ;PKA高活性抑制MPF活性 ,而抑制PKA活性则MPF活性高峰提前出现 .     

雌激素的心脏保护作用——与β1-肾上腺素受体的相互作用及其信号通路

雌激素是女性体内主要的类固醇性激素.对于心肌缺血性伤害,切除卵巢的成年雌性大鼠在β-肾上腺素受体激动时,比正常雌性大鼠呈现更严重的心肌损伤;而去卵巢后的雌激素替补组大鼠对β-肾上腺素受体激动时心肌缺血性伤害的反应则又回复到正常雌性大鼠水平,这为雌激素对抗缺血性伤害的心脏保护作用提供了证据.雌激素的这种保护作用是通过下调β1-肾上腺素受体的表达来实现的.也有研究证明,雌激素能抑制蛋白激酶A(protein kinase A,PKA)的表达和活性,PKA是Gs蛋白/腺苷酸环化酶(adenylyl cyclase,AC)/cAMP/PKA通路的第二信使,而该通路最终影响心肌的收缩功能.有初步证据表明雌激素还能抑制β1-肾上腺素受体通路下游的另一种第二信使钙调蛋白激酶Ⅱ-δc(Ca2+/calmodulin kinase Ⅱ-δc,CaMKⅡ-δc)的活性,而CaMKⅡ-δc参与PKA非依赖性的细胞凋亡.即时给予生理浓度雌激素可不通过雌激素受体而直接抑制心肌β1-肾上腺素受体并减弱Ca2+内流.此外,脑研究也显示雌激素能抑制负责调节动脉血压脑区的β广肾上腺素受体活性.因此,雌激素和β1-肾上腺素受体之间的相互作用及其信号通路十分复杂.雌激素不仅主导性别决定,在机体其它功能例如心脏保护方面也具有重要作用.     

cAMP/PKA诱导卵母细胞减数分裂停滞的机制

大多数物种的卵母细胞在减数分裂前都要经历长时间停滞,其中cAMP对卵母细胞减数分裂停滞具有重要作用,本研究关注c AMP对卵母细胞减数分裂的影响及其机制。本研究通过将卵母细胞与cAMP预孵育,再用胰岛素刺激研究胰岛素诱导的卵母细胞成熟的影响,接着本研究通过显微注射和Zeiss 100TV显微镜分析cAMP对PKA在卵母细胞中定位的影响,并且本研究用Western blotting的方法研究cAMP/PKA对mos蛋白的表达和MAPK蛋白磷酸化的影响。结果显示,本研究通过亲和层析得到了高纯度的PKA蛋白,且cAMP/PKA能够抑制卵母细胞的成熟,而PKA的热稳定抑制剂PKI能够解除PKA对卵母细胞减数分裂的抑制,cAMP/PKA也能够影响mos的积累以及MAPK的磷酸化。cAMP能够影响PKA在卵母细胞中的定位,cAMP/PKA能够通过影响mos积累抑制卵母细胞的减数分裂,这可能与cAMP能够抑制MAPK磷酸化有关。     

雌激素的心脏保护作用——与β1-肾上腺素受体的相互作用及其信号通路

雌激素是女性体内主要的类固醇性激素。对于心肌缺血性伤害,切除卵巢的成年雌性大鼠在β-肾上腺素受体激动时,比正常雌性大鼠呈现更严重的心肌损伤：而去卵巢后的雌激素替补组大鼠对β-肾上腺素受体激动时心肌缺血性伤害的反应则又回复到正常雌性大鼠水平,这为雌激素对抗缺血性伤害的心脏保护作用提供了证据。雌激素的这种保护作用是通过下调β1-肾上腺素受体的表达来实现的。也有研究证明,雌激素能抑制蛋白激酶A（protein kinaseA,PKA）的表达和活性,PKA是Gs蛋白／腺苷酸环化酶（adenylyl cyclase,AC）／cAMP／PKA通路的第二信使,而该通路最终影响心肌的收缩功能。有初步证据表明雌激素还能抑制β1-肾上腺素受体通路下游的另一种第二信使钙调蛋白激酶Ⅱ．δc（Ca^2＋/calmodulin kinaseⅡ-δc,CaMKⅡ-δc）的活性,而CaMKII-δc参与PKA非依赖性的细胞凋亡。即时给予生理浓度雌激素可不通过雌激素受体而直接抑制心肌β1-肾上腺素受体并减弱Ca^2＋内流。此外,脑研究也显示雌激素能抑制负责调节动脉血压脑区的β1-肾上腺素受体活性。因此,雌激素和β1-肾上腺素受体之间的相互作用及其信号通路十分复杂。雌激素不仅主导性别决定,在机体其它功能例如心脏保护方面也具有重要作用。     

RhoA蛋白和cAMP对人前列腺癌细胞株PC-3形态的影响(简报)

小G蛋白RhoA是细胞内信号转导的重要成分,参与对细胞的多种功能活动的调控。溶血磷脂酸(lysophosphatidicacid,LPA)与多种细胞的G蛋白偶连受体结合而发挥作用,除刺激细胞增殖外,还通过活化RhoA,诱导细胞骨架改变。cAMP是经典的第二信使,其下游激酶PKA可抑制RhoA活性,因此,cAMP在许多细胞活动中对RhoA有拮抗作用。本实验采用人前列腺癌细胞株PC-3,以绿色荧光蛋白(GreenFluorescentProtein,GFP)分别和不同RhoA结构(野生型RhoA、RhoA63L和RhoA188A)的cDNA共同转染细胞,在显微镜下(200倍视野)观察记录未转染细胞和转染细胞在LPA和cAMP作用下的形态变化,研究RhoA和cAMP/PKA介导的信号转导在调控癌细胞形态改变中的作用。     

康复训练对脑缺血大鼠运动功能恢复和脑组织cAMP-PKA信号通路的影响

目的观察康复训练对脑缺血再灌注大鼠运动功能及缺血灶周边脑组织cAMP、PKA表达的影响,探讨康复训练促进缺血性脑卒中运动功能恢复的分子机制。方法采用Longa改良线栓法制备大鼠大脑中动脉缺血再灌注模型（middle cerebral artery ischemia-reperfusion model,MCAO）,选择Bederson标准评分为1-3分的模型大鼠42只,随机分为自然恢复组（n=24）、康复训练组（n=18）,同时设立假手术组（n=12）。康复训练组大鼠于MACO术后48 h开始每天给予平衡木、转棒及滚筒训练。酶联免疫法（ELISA）检测缺血灶周围脑组织cAMP、PKA蛋白的表达,平衡木及网屏试验评定大鼠的运动功能。结果 （1）康复训练组缺血灶周围脑组织cAMP、PKA表达在术后7、14、21d均明显高于自然恢复组;（2）康复训练组大鼠的运动功能较自然恢复组明显改善。结论康复训练促进脑缺血再灌注大鼠的运动功能恢复,可能与cAMP-PKA信号通路活动有关。     

AKAP signaling complexes: getting to the heart of the matter

Subcellular compartmentalization of protein kinases and phosphatases through their interaction with A-kinase anchoring proteins (AKAPs) provides a mechanism to control signal transduction events at specific sites within the cell. Recent findings suggest that these anchoring proteins dynamically assemble different cAMP effectors to control the cellular actions of cAMP spatially and temporally. In the heart, signaling events such as the onset of cardiac hypertrophy are influenced by muscle-specific mAKAP signaling complexes that target protein kinase A (PKA), the cAMP-responsive guanine-nucleotide exchange factor EPAC and cAMP-selective phosphodiesterase 4 (PDE4). Mediation of signaling events by AKAPs might also have a role in the control of lipolysis in adipocytes, where insulin treatment reduces the association of AKAPs with G-protein-coupled receptors. These are only two examples of how AKAPs contribute to specificity in cAMP signaling. This review will explore recent development that illustrates the role of multiprotein complexes in the regulation of cAMP signaling.     

A-Kinase Anchoring Protein Targeting of Protein Kinase A and Regulation of HERG Channels

Adrenergic stimulation of the heart initiates a signaling cascade in cardiac myocytes that increases the concentration of cAMP. Although cAMP elevation may occur over a large area of a target-organ cell, its effects are often more restricted due to local concentration of its main effector, protein kinase A (PKA), through A-kinase anchoring proteins (AKAPs). The HERG potassium channel, which produces the cardiac rapidly activating delayed rectifying K(+) current (I (Kr)), is a target for cAMP/PKA regulation. PKA regulation of the current may play a role in the pathogenesis of hereditary and acquired abnormalities of the channel leading to cardiac arrhythmia. We examined the possible role for AKAP-mediated regulation of HERG channels. Here, we report that the PKA-RII-specific AKAP inhibitory peptide AKAP-IS perturbs the distribution of PKA-RII and diminishes the PKA-dependent phosphorylation of HERG protein. The functional consequence of AKAP-IS is a reversal of cAMP-dependent regulation of HERG channel activity. In further support of AKAP-mediated targeting of kinase to HERG, PKA activity was coprecipitated from HERG expressed in HEK cells. Velocity gradient centrifugation of solubilized porcine cardiac membrane proteins showed that several PKA-RI and PKA-RII binding proteins cosediment with ERG channels. A physical association of HERG with several specific AKAPs with known cardiac expression, however, was not demonstrable in heterologous cotransfection studies. These results suggest that one or more AKAP(s) targets PKA to HERG channels and may contribute to the acute regulation of I (Kr) by cAMP.     

Developmentally acquired PKA localisation in mouse oocytes and embryos

Localisation of Protein Kinase A (PKA) by A-Kinase Anchoring Proteins (AKAPs) is known to coordinate localised signalling complexes that target cAMP-mediated signalling to specific cellular sub-domains. The cAMP PKA signalling pathway is implicated in both meiotic arrest and meiotic resumption, thus spatio-temporal changes in PKA localisation during development may determine the oocytes response to changes in cAMP. In this study we aim to establish whether changes in PKA localisation occur during oocyte and early embryo development.Using fluorescently-labelled PKA constructs we show that in meiotically incompetent oocytes PKA is distributed throughout the cytoplasm and shows no punctuate localisation. As meiotic competence is acquired, PKA associates with mitochondria. Immature germinal vesicle (GV) stage oocytes show an aggregation of PKA around the GV and PKA remains co-localised with mitochondria throughout oocyte maturation. After fertilisation, the punctuate, mitochondrial distribution was lost, such that by the 2-cell stage there was no evidence of PKA localisation. RT-PCR and Western blotting revealed two candidate AKAPs that are known to be targeted to mitochondria, AKAP1 and D-AKAP2. In summary these data show a dynamic regulation of PKA localisation during oocyte and early embryo development.     

Small molecule AKAP-protein kinase A (PKA) interaction disruptors that activate PKA interfere with compartmentalized cAMP signaling in cardiac myocytes

A-kinase anchoring proteins (AKAPs) tether protein kinase A (PKA) and other signaling proteins to defined intracellular sites, thereby establishing compartmentalized cAMP signaling. AKAP-PKA interactions play key roles in various cellular processes, including the regulation of cardiac myocyte contractility. We discovered small molecules, 3,3'-diamino-4,4'-dihydroxydiphenylmethane (FMP-API-1) and its derivatives, which inhibit AKAP-PKA interactions in vitro and in cultured cardiac myocytes. The molecules bind to an allosteric site of regulatory subunits of PKA identifying a hitherto unrecognized region that controls AKAP-PKA interactions. FMP-API-1 also activates PKA. The net effect of FMP-API-1 is a selective interference with compartmentalized cAMP signaling. In cardiac myocytes, FMP-API-1 reveals a novel mechanism involved in terminating β-adrenoreceptor-induced cAMP synthesis. In addition, FMP-API-1 leads to an increase in contractility of cultured rat cardiac myocytes and intact hearts. Thus, FMP-API-1 represents not only a novel means to study compartmentalized cAMP/PKA signaling but, due to its effects on cardiac myocytes and intact hearts, provides the basis for a new concept in the treatment of chronic heart failure.     

D‐AKAP2:PKA RII:PDZK1 ternary complex structure: Insights from the nucleation of a polyvalent scaffold

A‐kinase anchoring proteins (AKAPs) regulate cAMP‐dependent protein kinase (PKA) signaling in space and time. Dual‐specific AKAP2 (D‐AKAP2/AKAP10) binds with high affinity to both RI and RII regulatory subunits of PKA and is anchored to transporters through PDZ domain proteins. Here, we describe a structure of D‐AKAP2 in complex with two interacting partners and the exact mechanism by which a segment that on its own is disordered presents an α‐helix to PKA and a β‐strand to PDZK1. These two motifs nucleate a polyvalent scaffold and show how PKA signaling is linked to the regulation of transporters. Formation of the D‐AKAP2: PKA binary complex is an important first step for high affinity interaction with PDZK1, and the structure reveals important clues toward understanding this phenomenon. In contrast to many other AKAPs, D‐AKAP2 does not interact directly with the membrane protein. Instead, the interaction is facilitated by the C‐terminus of D‐AKAP2, which contains two binding motifs—the D‐AKAP2_AKB and the PDZ motif—that are joined by a short linker and only become ordered upon binding to their respective partner signaling proteins. The D‐AKAP2_AKB binds to the D/D domain of the R‐subunit and the C‐terminal PDZ motif binds to a PDZ domain (from PDZK1) that serves as a bridging protein to the transporter. This structure also provides insights into the fundamental question of why D‐AKAP2 would exhibit a differential mode of binding to the two PKA isoforms.     

Anchored cAMP signaling: Onward and upward – A short history of compartmentalized cAMP signal transduction

Intracellular signal transduction pathways require a high degree of spatial and temporal resolution in order to deliver the appropriate outputs. Specific signaling mediated by the ubiquitous second messenger cAMP and its effector, the cAMP-dependent protein kinase (PKA), is governed by the spatial organization of different pathway components by A-kinase anchoring proteins (AKAPs). This review discusses the history and future of anchored cAMP signaling pathways.     

cAMP-PKA signaling to the mitochondria: protein scaffolds, mRNA and phosphatases

Energy metabolism and, specifically, the coupling of mitochondria to growth and survival is controlled by the cAMP-PKA pathway in yeast. In higher eukaryotes, cAMP signaling originating at the plasma membrane is distributed to different subcellular districts by cAMP waves received by PKA bound to PKA anchor proteins (AKAPs) tethered to these compartments. This review focuses on the subgroup of AKAPs that anchor PKA to the mitochondrial outer membrane (mtAKAPs). Only PKA anchored to mtAKAPs can efficiently transmit cAMP signals to mitochondria. mtAKAP complexes are remarkably heterogeneous. In addition to PKA regulatory subunits, they may include mRNAs, tyrosine phosphatase(s) and tyrosine kinase(s). Selective regulation of these components by cAMP-PKA integrates various signal transduction pathways and can determine which subcellular compartment receives the signal. Unveiling the interactions among the components of these large complexes will shed light on how cAMP and PKA regulate vital mitochondrial processes.     

Delineation of type I protein kinase A-selective signaling events using an RI anchoring disruptor

Control of specificity in cAMP signaling is achieved by A-kinase anchoring proteins (AKAPs), which assemble cAMP effectors such as protein kinase A (PKA) into multiprotein signaling complexes in the cell. AKAPs tether the PKA holoenzymes at subcellular locations to favor the phosphorylation of selected substrates. PKA anchoring is mediated by an amphipathic helix of 14-18 residues on each AKAP that binds to the R subunit dimer of the PKA holoenzymes. Using a combination of bioinformatics and peptide array screening, we have developed a high affinity-binding peptide called RIAD (RI anchoring disruptor) with >1000-fold selectivity for type I PKA over type II PKA. Cell-soluble RIAD selectively uncouples cAMP-mediated inhibition of T cell function and inhibits progesterone synthesis at the mitochondria in steroid-producing cells. This study suggests that these processes are controlled by the type I PKA holoenzyme and that RIAD can be used as a tool to define anchored type I PKA signaling events.     

Investigating PKA-RII specificity using analogs of the PKA:AKAP peptide inhibitor STAD-2

Generation of the second messenger molecule cAMP mediates a variety of cellular responses which are essential for critical cellular processes. In response to elevated cAMP levels, cAMP dependent protein kinase (PKA) phosphorylates serine and threonine residues on a wide variety of target substrates. In order to enhance the precision and directionality of these signaling events, PKA is localized to discrete locations within the cell by A-kinase anchoring proteins (AKAPs). The interaction between PKA and AKAPs is mediated via an amphipathic α-helix derived from AKAPs which binds to a stable hydrophobic groove formed in the dimerization/docking (D/D) domain of PKA-R in an isoform-specific fashion. Although numerous AKAP disruptors have previously been identified that can inhibit either RI- or RII-selective AKAPs, no AKAP disruptors have been identified that have isoform specificity for RIα versus RIβ or RIIα versus RIIβ. As a strategy to identify isoform-specific AKAP inhibitors, a library of chemically stapled protein-protein interaction (PPI) disruptors was developed based on the RII-selective AKAP disruptor, STAD–2. An alanine was substituted at each position in the sequence, and from this library it was possible to delineate the importance of longer aliphatic residues in the formation of a region which complements the hydrophobic cleft formed by the D/D domain. Interestingly, lysine residues that were added to both terminal ends of the peptide sequence to facilitate water solubility appear to contribute to isoform specificity for RIIα over RIIβ while having only weak interaction with RI. This work supports current hypotheses on the mechanisms of AKAP binding and highlights the significance of particular residue positions that aid in distinguishing between the RII isoforms and may provide insight into future design of isoform-selective AKAP disruptors.     

Essential role of A-kinase anchor protein 121 for cAMP signaling to mitochondria

A-Kinase anchor proteins (AKAPs) immobilize and concentrate protein kinase A (PKA) isoforms at specific subcellular compartments. Intracellular targeting of PKA holoenzyme elicits rapid and efficient phosphorylation of target proteins, thereby increasing sensitivity of downstream effectors to cAMP action. AKAP121 targets PKA to the cytoplasmic surface of mitochondria. Here we show that conditional expression of AKAP121 in PC12 cells selectively enhances cAMP.PKA signaling to mitochondria. AKAP121 induction stimulates PKA-dependent phosphorylation of the proapoptotic protein BAD at Ser(155), inhibits release of cytochrome c from mitochondria, and protects cells from apoptosis. An AKAP121 derivative mutant that localizes on mitochondria but does not bind PKA down-regulates PKA signaling to the mitochondria and promotes apoptosis. These findings indicate that PKA anchored by AKAP121 transduces cAMP signals to the mitochondria, and it may play an important role in mitochondrial physiology.